GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models--Novel mechanism of action, formulation and administration: Opaganib is a differentiated oral, non-peptide therapeutic that targets sphingosine kinase-2 (SPHK2), potentially avoiding common Glucagon-like peptide-1 (GLP-1) inhibitor side effects and administration burdens --Market ...

 Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss  Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “Study”) underway in Australia.  Enrollment of patients for all 5 Study arms has now been completed on schedule. Participation interest in the Stu ...

New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) ("the Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive early data from the open-label REVEAL-1 cohort of its on ...

The dietitian formulated, doctor-approved GLP-1 Support from Whole Health Rx™ by The Vitamin Shoppe® range of supplements delivers comprehensive nutritional solutions for individuals on GLP-1 weight- loss medications SECAUCUS, N.J., March 31, 2025 /PRNewswire/ -- The Vitamin Shoppe®, a leading omni-channel specialty retailer of nutritional products, today announced the launch of GLP-1 Support from Whole Health Rx™ by The Vitamin Shoppe®, an innovative line of dietary supplements designed to address the uniq ...

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes.While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly (LLY -2.98%) has emerged as one of the hottest stocks in th ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.When I last covered Structure Therapeutics (NASDAQ: GPCR ) in a note for Seeking Alpha back in August last year, I gave the South San Francisco-based biotech's stock a "Buy ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting weight became a viral sensation as type 2 diabetes medicine Ozempic kicked off the GLP-1 trend. Novo Nordisk A/S NYSE: NVO formulated a semaglutide treatment specially designed for obesity when they launched Wegovy in June of 2021. Eli Lilly & Co. NYSE: LLY launched its own GLP-1/GIP dual agonist treatment for obesity, ...

Novo Nordisk A/S NYSE: NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug Administration (FDA) to take semaglutide, the active ingredient in both, off the drug shortage list on February 21, 2025. This announcement sent shockwaves through shares of Hims & Hers Health Inc. NYSE: HIMS, triggering an immediate 25% sell-off on the news from $59.60 to $49.28 and continued to sink another 33% to ...

Core Insights - Teladoc Health has entered into a pharmacy integration agreement with Eli Lilly's LillyDirect pharmacy partner, Gifthealth, to enhance access to FDA-approved Zepbound® (tirzepatide) for members in its Comprehensive Weight Care Program [1][2] - The integration aims to provide seamless delivery of Zepbound® directly to patients' homes, ensuring visibility throughout the fulfillment process [2][3] - The partnership emphasizes the commitment to reducing barriers to high-quality care and providing affordable access to effective weight management treatments [3][4] Company Overview - Teladoc Health is a leader in virtual care, focusing on transforming healthcare experiences and improving health outcomes through personalized interactions and data-driven insights [6] - The company offers a Comprehensive Weight Care Program that includes multi-disciplinary support from licensed clinicians, registered dietitians, and health coaches, along with tools like connected digital scales and personalized lifestyle coaching [3][6] - The integration with LillyDirect and Gifthealth is part of Teladoc's strategy to enhance patient safety and sustainable health outcomes while avoiding risks associated with compounded medications [3][4]

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...